Catarinella F S, Nieman F H M, de Wolf M A F, Toonder I M, de Graaf R, Wittens C H A
Department of Venous Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands
Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, the Netherlands.
Phlebology. 2015 Mar;30(1 Suppl):89-94. doi: 10.1177/0268355515569431.
New developments in the treatment of complex deep venous disease have become available in the last decade. Besides analysing patencies as a surrogate outcome for these treatments we analysed the Quality-of-Life (QoL) changes for successful and failed deep venous treatments.
Patients with proven venous occlusive disease, referred to our department of Venous Surgery at the Maastricht University Medical Centre, were included. After inclusion patients were treated by percutaneous transluminal angioplasty and stenting and when indicated endophlebectomy with an arteriovenous fistula. QoL was assessed with the disease specific VEINES-QOL/Sym and the generic Short-Form (SF)-36 questionnaires preoperatively at baseline and post-operatively after 3, 12 and 24 months.
One hundred fifty-three interventions were analysed, showing a primary, assisted primary and secondary patency of respectively 65%, 78% and 89% at 24 months. The VEINES-QOL and Sym scores improved at 3, 12 and 24 months. The overall improvement at 24 months is 22.7 for QoL and 18.18 for Sym with respective p values of 0.013 and 0.016. The improvement of the VEINES-QOL and Sym scores after a successful (patent) treatment remained highly significant (QoL: p < 0.001, Sym: p = 0.004). Also the generic QoL (Short-Form 36v2) shows significant improvement after 12 months for physical functioning (p = 0.004) and role physical (p = 0.004) scales.
The overall patencies of interventions for deep venous pathology are exceptionally good after two years. Concomitantly the VEINES-Sym and VEINES-QOL scores improve significantly for 3, 12, and 24 months when compared to the baseline (T0) after treatment. Successful interventions showed, as expected, a significant greater QoL improvement between T0 and T3, T12, T24 for both VEINES-QOL and VEINES-Sym scores when compared to the failed interventions. The one-year linear improvement of two SF-36 scales (PF and RP) is also significant.
在过去十年中,复杂深静脉疾病的治疗有了新进展。除了分析通畅率作为这些治疗的替代结局外,我们还分析了深静脉治疗成功与失败后的生活质量(QoL)变化。
纳入马斯特里赫特大学医学中心静脉外科确诊为静脉闭塞性疾病的患者。纳入后,患者接受经皮腔内血管成形术和支架置入术,必要时行带动静脉瘘的静脉内膜切除术。术前基线时以及术后3、12和24个月,使用疾病特异性的VEINES-QOL/Sym问卷和通用的简短形式(SF)-36问卷评估生活质量。
分析了153例干预措施,24个月时的初次通畅率、辅助初次通畅率和二次通畅率分别为65%、78%和89%。VEINES-QOL和Sym评分在3、12和24个月时有所改善。24个月时生活质量的总体改善为22.7,Sym为18.18,p值分别为0.013和0.016。成功(通畅)治疗后VEINES-QOL和Sym评分的改善仍然非常显著(生活质量:p < 0.001,Sym:p = 0.004)。通用生活质量(简短形式36v2)在12个月后身体功能(p = 0.004)和角色身体(p = 0.004)量表也显示出显著改善。
两年后深静脉病变干预措施的总体通畅率非常好。同时,与治疗后的基线(T0)相比,VEINES-Sym和VEINES-QOL评分在3、12和24个月时显著改善。正如预期的那样,与失败的干预措施相比,成功的干预措施在T0与T3、T12、T24之间的生活质量改善在VEINES-QOL和VEINES-Sym评分方面都显著更大。两个SF-36量表(PF和RP)的一年线性改善也很显著。